Premium
P2‐154: Effects of Aerobic‐Strength Training on Selected Molecular Targets in Cerebrospinal Fluid of Seniors with Mild Cognitive Impairment
Author(s) -
Ukropcova Barbara,
Slobodova Lucia,
Vajda Matej,
Krumpolec Patrik,
Tirpakova Veronika,
Vallova Silvia,
Ondicova Katarina,
Sutovsky Stanislav,
Tsai Chia-Liang,
Pai Ming-Chyi,
Turcani Peter,
Valkovic Peter,
Sedliak Milan,
Ukropec Jozef
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1321
Subject(s) - aerobic exercise , medicine , cerebrospinal fluid , lumbar , physical therapy , physical fitness , strength training , cognitive impairment , physical medicine and rehabilitation , psychology , surgery , disease
Background:Cerebrospinal fluid (CSF) levels of total tau protein (hTau), phosphorylated tau (pTau181P), and amyloid-beta of 42 amino acids (Ab1-42) are established biomarkers for the diagnosis of Alzheimer’s disease (AD), but the discriminatory power for differential dementia diagnosis remains suboptimal. Also, current laboratory measures of CSF pTau181P are thought to underestimate the total levels of phosphorylated tau. The goal of this study is to investigate if the non-phosphorylated tau fraction (pTau rel) would improve the diagnostic performance of the routine AD biomarker panel for differential dementia diagnosis. Methods:The study population consisted of clinically diagnosed AD patients (n1⁄445), definite frontotemporal lobar degeneration (FTLD) patients (n1⁄445), definite Creutzfeldt-Jakob disease (CJD) patients (n1⁄420) and cognitively healthy controls (n1⁄420). CSF levels of Ab1-42, hTau, pTau181P and pTau rel were determined with commercially available single-analyte ELISA kits (INNOTEST b-Amyloid(142), INNOTEST hTau-Ag and INNOTEST Phospho-Tau(181P) from Fujirebio Europe, Belgium; pTAU rel ELISA Kit from AJ Roboscreen, IBL International GmbH, Germany). Receiver operating characteristic (ROC) curve analyses were used to obtain area under the curve (AUC) values. AUC values were compared using DeLong tests. Results:Diagnostic performance of single markers as well as biomarker ratios was determined for each pairwise comparison of different dementia groups and controls. To evaluate the diagnostic power of pTau rel in the routine AD biomarker panel, the single (routine) marker with the highest AUC value was compared with that of pTau rel. Additionally, the (routine) biomarker ratio with the highest AUC value was compared with its equivalent using pTau rel. An overview of the results is listed in Table 1. Conclusions: The diagnostic performance of pTau rel for differential dementia diagnosis (comparing AD, FTLD, CJD patients and healthy controls) is not better than the diagnostic performance of the routine AD CSF biomarkers.